Worldwide time trends in prevalence of symptoms of rhinoconjunctivitis in children: Global Asthma Network Phase I

• DOI: 10.1111/pai.13656
• Publication Date: 2021-08-28T16:41:10Z
• Authors: David P. Strachan; Charlotte E. Rutter; Monica Innes Asher; Karen Bissell; Chen‐Yuan Chiang; Asma El Sony; Eamon Ellwood; Philippa Ellwood; Luis García‐Marcos; Guy B. Marks; Eva Morales; Kevin Mortimer; Neil Pearce; Virginia Pérez‐Fe...; Steven Robertson; Richard J. Silver...
• Keywords: Adolescent; prevalence; Eczema; qw_900; wv_300; 03 medical and health sciences; rhinitis; 0302 clinical medicine; Surveys and Questionnaires; conjunctivitis; Prevalence; Humans; Child; Original Articles; Conjunctivitis; Asthma; time trend; 3. Good health; allergic disease; Cross-Sectional Studies; ww_160; wf_140; ws_280; wf_100

The Global Asthma Network (GAN), by using the International Study of and Allergies in Childhood (ISAAC) methodology, has updated trends prevalence symptoms childhood allergic diseases, including non-infective rhinitis conjunctivitis ('rhinoconjunctivitis'), which is reported here.Prevalence severity rhinoconjunctivitis were assessed questionnaire among schoolchildren GAN Phase I ISAAC III surveys 15-23 years apart. Absolute rates change estimated for each centre modelled multi-level linear regression to compare age group, time period per capita national income.Twenty-seven centres 14 countries surveyed 74,361 13- 14-year-olds ('adolescents') 45,434 6- 7-year-olds ('children'), with average response proportions 90% 79%, respectively. Many showed highly significant (p < .001) changes past year ('current rhinoconjunctivitis') compared ISAAC. direction magnitude centre-level varied significantly both within between countries. Overall, current decreased slightly from GAN: -1.32% 10 years, 95% CI [-2.93%, +0.30%] adolescents; -0.44% [-1.29%, +0.42%] children. Together, these differed upward trend Among adolescents, correlated those eczema (rho = 0.72, p .0001) but not asthma 0.15, .48). children, correlations positive significant.Symptoms may no longer be on increase globally, although vary substantially